Huntington's Disease News and Research

Latest Huntington's Disease News and Research

AMRI announces fourth-quarter and full-year 2009 results

AMRI today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.

8 Feb 2010

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

For the first time, researchers from the University of Pennsylvania School of Medicine have found that three different degenerative brain disorders are linked by a toxic form of the same protein. The protein, called Elk-1, was found in clumps of misshaped proteins that are the hallmarks of Parkinson's disease, Alzheimer's disease, and Huntington's disease.

3 Feb 2010

Mouse model demonstrates cell-to-cell connections between implanted stem cells and diseased cells

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research), the Karolinska Institutet, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School and Universit- Libre de Bruxelles have demonstrated in mouse models that transplanted stems cells, when in direct contact with diseased neurons, send signals through specialized channels that rescue the neurons from death.

2 Feb 2010

Scientists uncover a key cellular mechanism that alters brain cell function in Huntington's disease

Scientists at the Brain Research Centre and Centre for Molecular Medicine and Therapeutics have uncovered a key cellular mechanism that alters brain cell function in Huntington's disease, and identified a possible treatment for the disease.

28 Jan 2010

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.

28 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.

21 Jan 2010

HSF1A stimulates more protein chaperones and reduces protein misfolding

Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Metabolon awarded US Patent for ‘metabolomics methods’

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announced that it was awarded US Patent 7,635,556 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office on December 22, 2009.

18 Jan 2010

FDA approves TCA-CT's adult stem cell protocol for conducting Phase I clinical trials in ALS

TCA Cellular Therapy, LLC (TCA-CT) announced today that the U.S. Food and Drug Administration (FDA) has approved its adult stem cell protocol to conduct Phase I clinical trials to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).

18 Jan 2010

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

Israeli Minister of Science and Technology visits BrainStorm Cell Therapeutics; reviews ALS clinical trials

BrainStorm Cell Therapeutics Inc.(OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it received a visit yesterday by the Israeli Minister of Science and Technology, Professor Daniel Hershkowitz. The

12 Jan 2010

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

11 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Test tube experiments show slight changes in protein chemistry can eliminate Huntington's disease in mice

In Huntington's disease, a mutated protein in the body becomes toxic to brain cells. Recent studies have demonstrated that a small region adjacent to the mutated segment plays a major role in the toxicity. Two new studies supported by the National Institutes of Health show that very slight changes to this region can eliminate signs of Huntington's disease in mice.

28 Dec 2009

Key molecular switch linked to HD identified

Scientists have identified a key molecular switch that may drive the onset of Huntington's disease (HD), an incurable neurodegenerative disorder that leads to severe disruptions in muscle coordination and cognitive function. The research, published by Cell Press in the December 24 issue of the journal Neuron, enhances the understanding of HD pathogenesis and may direct new strategies for treating this devastating brain disease.

24 Dec 2009

Raptor Pharmaceutical completes $7.5 million registered direct offering

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced that on December 22, 2009, it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds (before placement agent fees and offering expenses) through the sale of 3,747,558 units.

24 Dec 2009

IKK phosphorylate: A double-edged sword in Huntington's disease

The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).

22 Dec 2009

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

Raptor Pharmaceutical Corp., today announced that it has entered into definitive agreements with institutional investors to purchase 3,747,558 units for gross proceeds of approximately $7.5 million, before placement agent fees and offering expenses.

19 Dec 2009

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

AMRI announces fourth-quarter and full-year 2009 results

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

Mouse model demonstrates cell-to-cell connections between implanted stem cells and diseased cells

Scientists uncover a key cellular mechanism that alters brain cell function in Huntington's disease

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

The American Journal of Pathology: Highlights from February 2010 issue

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

HSF1A stimulates more protein chaperones and reduces protein misfolding

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Metabolon awarded US Patent for ‘metabolomics methods’

FDA approves TCA-CT's adult stem cell protocol for conducting Phase I clinical trials in ALS

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Israeli Minister of Science and Technology visits BrainStorm Cell Therapeutics; reviews ALS clinical trials

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Test tube experiments show slight changes in protein chemistry can eliminate Huntington's disease in mice

Key molecular switch linked to HD identified

Raptor Pharmaceutical completes $7.5 million registered direct offering

IKK phosphorylate: A double-edged sword in Huntington's disease

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in